Author: Chen, Wenbo ; Chen, Jinglian ; Mo, Xianwei ; Wei, Xinjie ; Wang, Han ; Deng, Ying ; Luo, Tao ; Wei, Chunyin ; Tang, Weizhong ; Lai, Hao ; Lin, Qiuhua

ABSTRACTIntroductionIsobutyric acid (IBA), a short‐chain fatty acid, has been unequivocally demonstrated to exert significant influence on the progression of colorectal cancer (CRC). Nevertheless, a comprehensive understanding of its intricate regulatory mechanisms remains elusive.MethodsEmploying advanced techniques such as western blot, RT‐qPCR, and flow cytometry, we systematically investigated the impact of IBA on the expression of PD‐L1 in CRC cells. Concurrently, employing RNA silencing technology and small‐molecule inhibitors, we delved into the molecular intricacies underlying the regulatory axis of IBA involving ROCK1/c‐Myc/PD‐L1. Furthermore, through flow cytometry analysis, we examined the alterations in the tumor immune microenvironment following anti‐PD‐L1 antibody therapy in a murine tumor model treated with IBA.ResultsElevated levels of IBA were found to robustly activate PD‐L1 expression in CRC cells both in vitro and in vivo, concomitantly reshaping the tumor immune microenvironment. Subsequent mechanistic investigations unveiled that IBA, through its interaction and activation of ROCK1, promotes the activation of c‐Myc, thereby enhancing the transcription of PD‐L1. Silencing of ROCK1 and application of ROCK1 inhibitors effectively reversed the regulatory effects of IBA on PD‐L1. Additionally, IBA inhibited the activity of infiltrating CD8+ T cells, resulting in diminished antitumor immunity and attenuating the sensitivity to anti‐PD‐L1 therapy.ConclusionOur study elucidates a novel mechanism by which IBA inhibits the sensitivity of CRC to anti‐PD‐L1 antibody therapy. Emphasizing IBA and its downstream pathways as potential therapeutic targets for immune therapy resistance mechanisms, our findings provide a novel theoretical foundation for overcoming immune therapy resistance.

100 Deals associated with ROCK1 inhibitors(Medical University of Silesia)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	PL	Medical University of Silesia	02 Jul 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ROCK1 inhibitors(Medical University of Silesia)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation